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Abstract: 
BACKGROUND: Hallucinations and psychosis are common in patients with Parkinson's disease (PD), with 
reported prevalences of up to 48% and 80%, respectively. However, few randomized, double-blind, 
placebo-controlled trials evaluating the treatment options have appeared in the literature. The studies 
that have been published were complicated by lack of agreement on the diagnosis of psychosis in PD, 
poor completion rates, mixed populations that included dementia, and other issues. Several reviews, 
guidelines, and consensus statements have sought to establish standards for treating these symptoms of 
PD. In 2006, the American Academy of Neurology (AAN) published a practice guideline (based on articles 
published up to 2004) for management of depression, psychosis, and dementia in patients with PD. 
Since then, a number of relevant studies have been published. OBJECTIVE: The purpose of this article 
was to review data that have appeared in the literature since publication of the AAN guideline regarding 
the management of hallucinations and psychosis in PD. METHODS: A literature search of the PubMed, 
CINAHL, and PsychInfo databases was conducted for human studies published in English from January 
2004 to June 2010. All clinical studies were included except case reports and case series. Studies with 
<20 participants were also excluded. Search terms included psychosis, hallucinosis, hallucination, 
delusion, Parkinson, atypical antipsychotic, neuroleptic, aripiprazole, clozapine, olanzapine, quetiapine, 
risperidone, and ziprasidone. RESULTS: Thirteen studies were included in the review: 3 studies of 
clozapine, 7 studies of quetiapine, 2 head-to-head trials comparing quetiapine and clozapine, and 1 
noncomparative trial of clozapine or quetiapine interventions. Most of the studies included participants 
with a mean age in the early to mid 70s and a mean duration of PD typically >10 years. CONCLUSIONS: 
Results of the identified studies suggested that patients with PD might benefit from long-term clozapine 
therapy. Results of the quetiapine studies were conflicting. However, no statistically significant 
difference in effectiveness was found between quetiapine and clozapine in comparative trials. The 
significance of the differences in treatment responses between patients with dementia and those 
without dementia remains unclear, and it was not possible to draw conclusions for or against other 
atypical antipsychotics because of insufficient evidence. Further studies are needed to address the 
methodologic issues in the current trials and to assess safety issues in larger cohorts. 
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Management of Hallucinations and Psychosis 
Parkinson's Disease 
Marty l. Eng, PharmD; and Timothy E. Welty, MA, PharmD 
. 
m 
Department of Pharmacy Practice, University of Kansas School of Pharmacy, Kansas City, Kansas 
ABSTRACT 
Background: Hallucinations and psychosis are common in patients ~th Parkinson's disease (PO), with reported 
prevalences of up to 48% and 80%, respectively. However, few randomized, double -blind, placebo controlled trials 
evaluating the treatment options have appeared in the literature. fie studies that have been published were compli-
cated by lack of agreement on the diagnosis of psychosis in to, r completion rates, mixed populations that in-
cluded dementia, and other issues. Several reviews, guidelines. a consensus statements have sought to establish 
standards for treating these symptoms of PD. In :2006, the American Academy of Neurology (AAN ) published a 
practice guideline (based on articles published up to 2004) for management of depression, psychosis, and dementia 
in patients with PD. Since then, a number or-relevant studies have been published. 
Objective: The purpose of this article was t revie.w data that have appeared in the literature since publication of 
the AAN guideline regarding the management of hallucinations and psychosis in PD. 
Methods: A literature search of the Pu.!'Med, CINAHL, and Psychlnfo databases was conducted for human stud-
ies published in English from January 200 t01une 2010. All clinical studies were included except case reports and 
case series. Studies with <20 participants were also excluded. Search terms included psychosis, hallucinosis, hallucina-
tion, delusion, Parkinson, atypical antipsychotic, neuroleptic, aripiprazole, clozapine, olanzapine, quetiapine, risperi-
done, and ziprasidone. 
Results: Thirteen studies were included in the review: 3 studies of clozapine, 7 studies of quetiapine, 2 head-to-
head trials comparing quetiapine and c1ozapine, and 1 noncomparative trial of c10zapine or quetiapine interventions. 
Most of the studies included participants with a mean age in the early to mid 70s and a mean duration of PO typi-
cally >10 years. 
Conclusions: Results of the identified studies suggested that patients with PO might benefit from long-term 
clozapine therapy. Results of the quetiapine studies were conflicting. However, no statistically significant difference 
in effectiveness was found between quetiapine and clozapine in comparative trials. The significance of the differences 
in treatment responses between patients with dementia and those without dementia remains unclear, and it was not 
possible to draw conclusions for or against other atypical antipsychotics because of insufficient evidence. Further 
studies are needed to address the methodologic issues in the current trials and to assess safety issues in larger cohorts . 
(Am J Geriatr Pharmacother. 201O;8:XXX-XXX) © 2010 Excerpta Medica Inc. 
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INTRODUCTION 
Psychotic symptoms such as hallucinations and delu-
sions are common in patients with Parkinson's disease 
(PO) . The estimated prevalence of hallucinations rang-
es from - 10% to 48%, and the prevalence of delusions 
ranges from 3% to 80%.1-9 Risk factors for the develop-
ment of psychotic symptoms include cognitive impair-
ment, dementia, age >65 years, advanced disease (>6 
years' duration), advanced PO (Unified Parkinson Dis-
ease Rating Scale [UPDRS] score >44.5), presence of 
sleep disorders, concomitant depression, ocular dys-
function, fumily history of dementia, use of dopamine 
agonists, and axial parkinsonism.1Q--13 
Recently, Ravina et aJl4 developed diagnostic criteria 
for psychosis in PD. The characteristic symptoms in-
clude ~ l of the following: illusions, false sense of pres-
ence, hallucinations, and delusions. The clinical defini-
tion of psychosis in PO also must include a primary 
diagnosis of PO using the UK Brain Bank Criteria, and 
the onset of symptoms must occur after the diagnosis 
of PD. In addition, psychotic symptoms must be recur-
rent or continuous for ~l month. These criteria rule 
out delirium and brief psychotic disorders. Associated 
features (eg, insight, dementia, PO treatment) may also 
be present and should be specified at the time of diag-
nosis. Other causes of psychotic symptoms that shoula 
be excluded are dementia with Lewy bodies (DLBb 
delirium, schizophrenia, schizoaffective disorder,delu-
sional disorder, and mood disorder with psychotic fea-
tures. Visual hallucinations tend to be more common 
but are often minor and less disruptive than delu-
sions/,14 Both hallucinations and psychosis have been 
reported to persist throughout the course of PD.15,16 
These psychotic symptoms have been associated with 
increased caregiver burden, nursing home placement, 
and risk of death.!1-19 
Despite the high prevalence of hallucinations and 
delusions in PO, few randomized controlled trials 
(RCTs) have been published. Previous studies have 
typically been case studies, case series, retrospective and 
prospective observational studies, and open·label stud-
ies. The limitations inherent with such data create clini-
cal uncertainties . 
In 2006, Miyasaki et al20 developed and published 
the American Academy of Neurology (AAN) practice 
guideline for the management of psychosis in PO in 
accordance with AAN standards for guideline develop-
ment.2! They concluded that clozapine should be con-
sidered for use based on one class I study and one class 
II study (comparison with quetiapine).22,23 Based on a 
comparative trial of clozapine and quetiapine,23 the 
2 
recommendation was that quetiapine may be consid-
ered for use based on a lack of significant difference in 
effectiveness. Finally, it was recommended to avoid 
olanzapine because of a lack of response in treating 
psychotic symptoms and worsening of PO motor symp-
toms in 2 class II studies.24,25 
The 2006 guideline included studies published be-
fore 2004. Because class I and II evidence was available, 
weaker, open-labeled studies and the plethora of case 
reports (class III or IV studies) were not included in 
the development of the guideline. Based on the guide-
line, clozapine or quetiapine may be used for hallucina-
tions and psychosis. However, it is not clear which 
subgroups of patients would benefit from pharmaco-
logic treatment or how long treatment should persist. 
For example, in Alzheimer's disease, behavioral and 
psychological symptoms of dementia (BPSD) appear to 
wax and wane in mild to moderate disease.26,21 This 
allows for discontinuation of treatment or periodic 
dose reductions to minimize patient exposure to medi-
cations However, in PO, BPSD have been reported to 
be persistent.1s,y; 
The olSjective of this article was to review data that 
have ap~ared in the literature since publication of the 
AAN IDIideline regarding the management of halluci-
nations and psychosis in PD. 
PATIENTS AND METHODS 
The AAN guideline is based on studies published be-
fore 2004. Therefore, to review the subsequently pub-
lished literature, a search of the PubMed, CINAHL, 
and Psych Info databases was conducted for articles 
published between January 2004 and June 2010. The 
search was limited to English language and human 
studies. The following search terms were used: psychosis, 
hallucinosis, hallucination, delusion, Parkinson, atypical 
antipsychotic, neuroleptic, aripiprazole, ciozapine, olan-
zaprine, quetiapine, risperidone, and ziprasidone. All 
study designs were included except case reports, case 
series, and studies with <20 participants. References 
from published articles also were searched. Both au-
thors reviewed the identified articles for inclusion in the 
review. Where disagreement about inclusion occurred, 
both authors met to review the criteria and resolve the 
difference of opinion. All published outcomes were 
included in the analysis of data. 
The most commonly used scale in the reviewed stud-
ies was the Brief Psychiatric Rating Scale (BPRS).28 
Other scales included the Baylor Hallucination Ques-
tionnaire (BPDHQ; not validated), the Clinical Global 
Impression of Improvement (CGI) or Severity of Ill-
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ness (CGI-SI),29 the Hoehn and Yahr (H&Y),30 the 
Mini-Mental State Examination (MMSE),31 the Neu-
ropsychiatry Inventory (NPI-Total [sum of all scores] 
and NPI-2 subscale [sum of hallucinations and delu-
sions item scores]), 32 Parkinson's Psychosis Rating 
Sc31e (PPRS),33 the Positive and Negative Symptoms 
Sc31e (PANSS),34 and the UPDRS (total, motor, and 
ADL).35 All of these scales except the CGI assess the 
severity and frequency of psychotic symptoms. Al-
though all are frequently used in PD psychosis research, 
only the PPRS is validated in a PD population. The 
PPRS, BPDHQ, and CGI require application by spe-
cially trained clinicians; no standardized cutoffi exist 
for these scales as they do for the MMSE and other 
scales . 
Scores for the scales used in these studies were as fol-
lows: BPDHQ (each item rated 0-4; higher scores in-
dicate worse symptoms); BPRS (range, 0- 108 if using 
0-6 scale or 18-126 if using 1-7 scale; each of 18 items 
rated from not present to extremely severe); CGI 
(range, 0-7; 0 - not assessed, 4 - no change, 7 _ very 
much worsened); CGI-SI (range, 0-7; 0 - not as-
sessed, 1 - normal, 7 - extremely ill); H&Y (range, 
1-5; lower scores indicate higher functioning); Index 
of ADL (6 domains of functioning; higher scores indi-
cate worse function [secondary outcome]); MMSE 
(range, 0-30; dO - severe, 10-20 - moderate(20-26 
- mild, >26 - normal; higher scores indicate'lohigher 
function); NPI-Total tot31 sum of scores (range, 
0-120; subscales for frequency [4-point scale; 4 _ very 
frequent] and severity [3-point scale; 3 _ severe]); 
NPI-2 (~1 on hallucination or delusion subscales con-
sidered c1inic31ly important [secondary outcome]); 
PANSS (range, 16-112; 58 - mildly ill, 75 - moder-
ately ill, 95 - markedly ill, 116 - severely ill ; each item 
rated 1-7, with 1 being absence of symptoms and 7 
being most severe symptom); PPRS (range, 6-24); 
UPDRS-Total (range, 0-108; each item rated from 
normal [0] to severe [4]; decreases in score indicate 
improvement); UPDRS-ADL subscale (13 items rated 
on a scale of 0-4, with 0 representing normal or best 
status); and UPDRS-Motor subscale (18 items; lower 
scores indicate better motor function). 
RESULTS 
Thirteen studies were included in the review: 3 studies 
of c1ozapine,36-38 7 studies of quetiapine,39-45 2 head-
to-head trials comparing quetiapine and c1ozapine!6,47 
and 1 noncomparative trial of c10zapine or quetiapine 
interventions.48 Baseline demographic characteristics of 
the patients in these studies are presented in Table I. 
Most of the studies included participants with a mean 
age in the early to mid 70s and a mean duration of PD 
typic31ly >10 years. Studies varied in the reporting of 
PD function based on the UPDRS-Total score and the 
H&Y score . The mean levodopa doses ranged from 
300 to 788 mg! d; most doses were between 600 and 
788 mg! d. Only one study'° reported low doses (me-
dian, 300-400 mg/d). Three studies37,41,45 did not 
report mean levodopa doses. The duration of therapy 
in the studies of PD psychosis was typically -3 months 
but ranged from 2.5 to 60 months. Studies were con-
ducted with clozapine and/or quetiapine; no studies of 
aripiprazole, olanzapine, risperidone, or ziprasidone 
met the inclusion criteria. Based on the reported UP-
DRS-Total, H&Y, and UPDRS-Motor scores, high 
daily levodopa doses, and the duration of disease, study 
patients were typically classified as having moderate to 
advanced PD. However, definitions of psychosis varied 
among studies, even after publication of the 2007 
Ravina criteria.14 
THe study designs and outcomes of the identified 
trials a!( presented in Tables IT to V. Most of the stud-
i~used the change in BPRS-Total score from baseline 
to end point as the primary outcome measure of psy-
chotic symptoms and the UPDRS-Motor score to de-
termine the influence of treatment on motor symptoms 
and tolerability. The mean BPRS scores at baseline 
ranged from 11 to 40.5; higher scores indicated more 
severe symptoms. Six studies36-39,43,47 did not report 
baseline BPRS scores. One study'7 reported the follow-
ing baseline NPI scores: hallucination frequency - c10-
zapine 3.0, quetiapine 3.1; hallucination severity -
c10zapine 1.3, quetiapine l.4; delusions/frequency -
c10zapine 3.0, quetiapine l.5; and delusions/severity -
c10zapine 2.0, quetiapine l.5 (311, P - NS) . One studyM 
reported a baseline PANSS score of 15.3 in the placebo 
group and 17.8 in the c10zapine group (P value not re-
ported) . Thus, 4 studies37-39,43 did not present informa-
tion regarding baseline frequency or severity of psychotic 
symptoms. Other outcome measures included the BP-
DHQ, CGI, nursing home placement, and death. 
Adverse effects were rare in these studies. However, 
interpretation of the safety data was limited by the sm31l 
sample sizes, which might have decreased the power to 
detect rare but serious adverse effects . In addition, ad-
verse effects were poorly described among the identi-
fied studies. Six of the 13 studies reported actual num-
bers of patients experiencing worsening of motor 
symptoms.36,3Hl ,46 Among these studies, 11.8% 
(28/238) of the patients were reported to experience 
worsening of motor symptoms; of the 28 patients, 3 
3 
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Table I. Bas~ine demographic characteristics of the study populations.}6-48 
Levodopa PD Duration, 
Study Mean Age, Years UPDRS-Total H&Y UPDRS-Motor Dosage, mg/d Years 
Clozapine Studies 
Pollak et at Clozapine, 71.2; Clozapine, 52.6; Clozapine, 3.3; Clozapine, 31.5; Clozapine, 788; Clozapine, 12.1; 
200416 placebo, 72.8 placebo, 52.7 placebo, 3.1 placebo, 31.4 placebo, 733 placebo, 11.3 
Fernandez et at 76 NA 3.5 39.4 NA 14.2 
2oo4J7 
Gomideetat 64 55 3. NA 762.5 13.8 
2oo8~ 
Quetiapine Studies 
Mancini et at 69.4 NA 2.9 (on), 35.2 (on), 714.7 11.7 
2oo4J9 3.6 (off) 50.8 (off) 
Juncoset at 73 55.8 NA 27.8 Median, 300-400 NA 
200440 
Ondo et at Quetiapine, 74; NA NA Quetiapine, 34; NA Quetiapine, 12; 
200541 placebo, 71 placebo, 31 placebo, 9 
Prohorov et at 75.5 NA NA Dementia,40.9; 685.3 10.3 
200642 no dementia, 
36.5 
Klein et at 76.1 NA NA 38.5 685.3 10.3 
2006° QUetiaPin~.2; Rabeyet at Quetiapine, 75.5; Quetiapine, 64.9; Quetiapine, 37; Quetiapine, 594.6; Quetiapine, 10.5; 
200744 placebo, 74.5 placebo, 69.2 p'lacebO, 3.2) placebo, 39.5 placebo, 766.1 placebo, 10.6 
Kurian et at Quetiapine, 73.5; NA NA Quetiapine, 17.2; NA NA 
200745 placebo, 74.1 placebo, 17.5 
Comparison Studies 
Morgante et at Quetiapine, 70; NA NA Quetiapine, 53; Quetiapine, 710; Quetiapine, 8.3; 
2004.% clozapine,69 clozapine, 58 clozapine, 687 clozapine, 9.6 
Merims etal 71.8 Clozapine, 78.4; 2.9 NA Clozapine, 691; 10.3 
200647 quetiapine, 75.3 quetiapine,778 
Noncomparative Trial of Clozapine or Quetiapine Interventions 
Goetz et at 72 NA NA 40 802 12 
200843 
UPDRS-Total = Unified Parkinson'sDisease RatingScale-Total (range. 0-108;each item rated from normal 10] to severe 14~ decreases in score indicate improve-
ment}. H&Y = Hoehn and Yahr (range, 1-5; lower scores indicate higher functioning); UPDRS-Motor subscale (18·items; lower scores indicate better motor 
function}. PD = Parkinson'sdisease; NA = not assessed. 
received placebo and 25 received an atypical antipsy-
chotic medication. However, all of these worsenings 
were described by the study investigators as not suffi-
cient to alter or discontinue treatment. The remaining 
7 studies, which did not report actual numbers, made 
statements such as "no significant difference in UPORS 
(motor)" scores.37,42-45,47,48 
, 
Clozapine Studies 
Three studies examined clozapine in the treatment of 
psychosis in patients with PD.36-38 In 2004, Pollak et 
al36 conducted a multiphase RCT in 60 patients with 
PO to determine the effectiveness and tolerability of 
clozapine in drug-induced psychosis. At baseline, the 
mean age of study participants was -71 years, the dura-
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tion of PO was - 11 to 12 years, H&Y stages were 3.1 
to 3.3, and the UPORS-Total score was 52 points. The 
mean baseline PANSS score was 17.8 for the c10zapine 
group and 15.3 for the placebo group. Treatment oc-
curred in 4 phases. Phase 1 was a screening period, 
during which patients were started on a low dose of 
clozapine (6.25 mg once daily) or placebo at bedtime. 
Phase 2 was a dose-titration period. Doses were in-
creased at a rate of 12.5 mg/d to a maximum of 50 
mg/d. The mean dose at the end of phase 2 was 35.8 
mg/d (range, 12.5-50 mg/d). The dose of clozapine 
could be reduced during phase 2 if the patient experi-
enced adverse effects. If no improvement was experi-
enced after 2 weeks, patients entered phase 3, which 
was open labeled. Patients in the clozapine group con-
tinued with dose titration up to a maximum of 100 
mg/d, and those in the placebo group were started on 
clozapine. The mean dose during phase 3 in those who 
previously received c10zapine was 40 mg/d (range , 
12.5- 100 mg/d); the mean dose in those who previ-
ously received placebo was 42.5 mg/d (range , 6.25-
100 mg/d). Finally, if patients exhibited "mental nor-
malization," as evidenced by a score of <3 on PANSS 
items PI and P3 (which correspond to hallucinations 
and delusions), c10zapine was discontinued over a week 
and the patients were followed for 3 weeks. The com-
pletion rate was poor (76.7%; 46/60). Results.:. of the 
study are summarized in Table II. At the enCl'of hase 
2, patients who received c10zapine had a - .8-poiIJJ 
improvement in CGI score over baseline (P < 0.001 ) 
and patients who received placebo had a...0.6-~int im-
provement (P - 0.011 ). The change in'p SS score 
from baseline to the end of phase 2 decreased by 5.6 
points (P < 0.001) in the c10zapine group and by -0.8 
points (P - NS) in the placebo group. Statistically sig-
nificant differences were also found between the groups 
in the changes in the CGI ( l.8 -point improvement for 
clozapine vs 0.6-point improvement for placebo; P < 
0.001 ) and the PANSS (5.6 for c10zapine vs 0.8 for 
placebo; P < 0.001 ). At the end of phase 3, the CGI 
and PANSS scores continued to improve in patients in 
the c10zapine titration group, by - 2.5 points (P < 
0.001 ) and - 7.7 points (P < 0.001 ), respectively. At the 
end of phase 3, the group that switched from placebo 
to c10zapine had a - 1.8-point improvement in CGI 
score (P < 0.001 ) and a -4.8-point improvement in 
PANSS score (P < 0.001 ). Twenty-fi ve patients entered 
phase 4 for withdrawal of therapy. Relapse was ob-
served within 3 months in 76.0% (19/25) of patients. 
Overall, adverse effects and serious adverse effects oc-
curred more frequently in the c10zapine group than in 
the placebo group. Somnolence at the end of phase 2 
occurred more frequently in c10zapine users (53 .1 %; 
17/32) than in placebo users (17.9%; 5/28). Somno-
lence in phase 3 occurred more frequently in patients 
who switched from placebo to clozapine (44.0%; 
11/ 25) than in those who continued c10zapine titra-
tion (10.0%; 3/30) (P value not reported). Worsening 
of PO symptoms at the end of phase 2 was reported in 
2l.9% (7/32) of c10zapine users and 3.6% (1/ 28; P -
NS ) of placebo users. At the end of phase 3, worsening 
of PO was not substantially different between patients 
in the c1ozapine-titration group (13.3%; 4/30) and 
those switching from placebo to c10zapine (12.0% 
[3/25]; Pvalue not reported). Sialorrhea also occurred 
more frequently in the c10zapine group (9.4%; 3/32) 
than in the placebo group (0%; 0/ 28) at the end of 
phase 2 and occurred in 20.0% (5/25) of those who 
switched from placebo to c10zapine versus none of 
those cominuing c10zapine titration (0%; 0/30) at the 
end of hase 3. Serious adverse effects occurred in 4 
patients sUGden death, death from pneumonia, aggres-
sion \vith delusions, and confusion \vith delusions; 1 
patient each). These events led to discontinuation of 
treatmr t in phase 3, but the investigators did not 
s~,W whether they were deemed to be treatment 
related. 
Fernandez et a137 also reported on clozapine use in 
patients with PO and psychosis. This descriptive retro-
spective chart review included 39 patients with PO and 
psychosis; 79 .5% (31/39) of the patients had probable 
PO, 12.8% (5/39) had OLB, and 7.7% (3/39) had 
other parkinsonian features. More than half of the co-
hort (56.4%; 22/39) also had dementia. Outcomes 
were nursing home placement and mortality after 5 
years. The mean age of the cohort was 76 years, and 
the mean duration of PO was 14.2 years . The mean 
dose of c10zapine was 47 mg/d, with a mean treatment 
duration of 5 years. The investigators reported nursing 
home placement for 33.3% (13/39) of patients and a 
mortality rate of 43.6% (17/39) at 5 years . Partial/ 
good response was reported for 84.6% (33/39) of the 
patients, and 12.8% (5/39) had complete resolution of 
psychosis with c10zapine treatment (P value not re-
ported). The measurements of response were not de-
scribed in the publication. Significant worsening of 
motor symptoms over baseline based on UPORS-Mo-
tor scores (39.5 vs 45 .7; P < 0.001 ) was reported at the 
end of the study. This was also true for H&Y scores 
(3.4 vs 3.9; P - 0.006). However, it was also noted that 
none of the patients discontinued c10zapine treatment 
because of worsening motor function. The most com-
s 
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mon adverse effects were sedation and siaJorrhea (30% 
and 10%, respectively). 
Gomide et al3s retrospectively reviewed the charts of 
43 patients with PO who used c1ozapine: 17 with dys-
kinesia, 15 with psychosis, and 11 with both diagnoses. 
The purpose of this study was to describe the character-
istics of clozapine users in a Brazilian cohort. Although 
Table ll. Clozapine studies.}6-38 
Mean Dose 
Cohort Completion (Range), 
Study Blind Size Rate, % mgld 
Pollak et at Fm 60 76.7 Phase 2: 
2oo4}6 phase 2 clozapine, 
only 35.8 
(12.5-50); 
placebo, 
41.7 (6-50); 
phase 3: 
clozapine, 
40 
(12.5-100); 
placebo, 
42.5 
(6.25-100) 
Fernandez No 39 47 
et at 200437 
Gomide No 43 69.6 
et at 200838 (12.5-225) 
"improvement" was reported, it is not clear what mea-
sures were used to determine improvement. Of the 
patients with psychosis, 73.3% (11/15) had at least 
partial improvement and 13.3% (2/15) experienced no 
change. (Two patients were unaccounted for in the 
originaJ article.) This appeared to be a globaJ impres-
sion among clinicians. However, the text was ambigu-
Primary Outcomes 
Duration, Outcome 
Months Measures Primary Secondary 
Phase 2, 1; CGI, Phase 2 change in CGI 76% (19/25) 
phase 3, 3; PANSS from baseline: clozapine, Relapsed in 
phase 4, P < O.(X)1; placebo, phase 4 
0.25 P < 0.01; phase 2 change 
in PANSS from baseline: 
clozapine, P < Q001; 
placebo, P < Q 127 
between treatment 
groups; differences from 
baseline on both CGI 
and PANSS, P < 0.001; 
phase 3 change in CGI 
from baseline: clozapine 
to clozapine, P < 0.001; 
placebo to dozapine, 
P < 0.001; phase 3 change 
in PANSS from baseline: 
clozapine to clozapine, 
P < 0.001; placebo to 
clozapine, P < 0.001 
60 NH admit 33% Admit to NH; 
5-year 44% mortality over 
mortality 5 years 
26% Remained on 67.5% 
clozapine x 3.5 years Improved 
and 40% < 1 year psychosis; 
60.5% noticed 
adverse effects; 
7 stopped 
treatment due 
to adverse 
effects 
CGI = Clinical Global Impression of Improvement (range. 0-7; 0 = not assessed. 4 = no change. 7 = very much worsened}, PANSS = Positive and Negative 
Syndrome Scale (range. 16-112; ~ = mildly ill. 7S = moderately ill. 95 = markedly il~ 116 = severely il~ each item rated 1-7, with 1 being absence of symptoms 
and 7 being most severe symptom}, NH = nursing home. 
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ous in describing the assessment of effectiveness; no health care system that could introduce potentiaJ biases 
scales were used to assess psychotic symptoms. The in the results. In terms of tolerability, dozapine treat-
external vaJidity of the study results was limited because ment was stopped in 20 patients (5 due to death, 7 due 
data regarding baseline severity of psychotic symptoms to adverse effects of d ozapine, 2 due to worsening of 
was not presented. It was also not clear what differ- motor function, and 6 for reasons not described). Ad-
ences in care might have occurred within the Brazilian verse effects leading to discontinuation of treatment 
Table III. Quetiapine studies.l 9-"S 
Duration Primary 
Cohort BPRS- Completion Mean Dose (Range), Outcome 
Study Blind Size Total Rate, % (Range), mg/d Months Measures Results 
Mancini et at No 35 NA 91.4 185 12 UPDRS- III UPDRS, P = NS; PPRS, 
2004J9 (motor), P < 0.001; MMSE, P = NS 
PPRS, 
MMSE 
Juncoset at No 29 17.8 86.2 62.5 5.6 BPRS, Mean change: BPRS, -6 
200440 (12.5-400) ~7) NPI-Total (P = 0.0031 NPI-Total-7 
NPI-2, (P = NS); NPI-2, -3.9 
CGI-SI (P = 0.0271 CGI-SI, -0.5 
(P = 0.039) 
Ondoet at Yo. 31 11 83.8 Up to 200 3 BPDHQ, BPDHQ, P = NS; UPDRS, 
200541 UPDRS P= NR 
Prohorov et al No 35 35.5 69 Dementia, 150.9; 6 BPRS,CGI BPRS: No dementia, P = NS; 
200642 no dementia, 76.3 dementia, no change 
reported; CGt improved; 
no dementia, 25% (4/16); 
no statistics reported 
Klein et at No 35 NA 93 24 CG I Overall 42.9% (15/35) rated 
200643 as good or partial response; 
(extension dementia, 46.7% (7/15) 
of study by had good response; no 
Prohorov dementia, 44% (4/9) had 
et a1( 2) 
good or partial response 
Rabeyet at Yo. 58 24-26 55 119 3 BPRS,CGI BPRS: No change; 9/29 
200744 (31%) improved quetiapine, 
13/27 (48%) improved 
placebo 
Kurian et at Yo. 40 26.5 75 120 2.5 BPR$ P= NS 
200746 
BPRS = Brief Psychiatric Rating Scale (range, 0-108 if usingO-6 scale or 18-126 if using 1-7 scale;each of 18 items rated from not present to extremely severe}. 
NA = not assessed; UPDRS = Unified Parkinson Disease Rating Scale (range, 0-108; each item rated from normal (OJ to severe [4~ decreases in score indicate 
improvement}. UPDRS-III (motor) = subsection ofUPDRSthat assesses motor function (14 items using a scale of 0-4, with 4 being the worst level offunction-
ins); PPRS = Parkinson Psychosis Rating Scale (range, 6-24}. MMSE = Mini-Mental State Examination (range, 0-30; <10 = severe, 10-20 = moderate, 20-26 
= mild, >26 = norma~ higher scores indicate higher function); NPI-Total = Neuropsychological Inventory total sum of scores (range, 0-120; subscales for fre-
quency [4-point scale; 4 = very frequent] and severity (3-point scale; 3 = severe)); :>: 1 on hallucination or delusion subscales considered clinically important}. 
NPI-2 = NPI sum of hallucinations and delusions item scores (:>:1 on hallucination or delusion subscales considered clinically important); CGI-SI = Oinical 
Global Impression-Severity ofiliness(range, 0-7; 0 = not assessed, 1 = norma~ 7 = extremely ill}. BPDHQ = Baylor PO Hallucination Questionnaire (each item 
rated 0-4; higher scores indicate worse symptoms}. NR = not reported; CGI = Clinical Global Impression of Improvement (range, 0-7; 0 = not assessed, 4 = no 
change, 7 = very much worsened} 
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included neutropenia (3 patients), thrombocytopenia 
(1 ), severe constipation with bowel obstruction (1), 
hallucination (1), and agitation (1). Thus, adverse ef-
fects in this study appeared to limit the effectiveness of 
clozapine given that 46.5% (20/ 43 ) of patients had to 
stop treatment. 
Quetiapine Studies 
Seven quetiapine studies39-45 were included in this 
review (Table TIl). Mancini et al39 reported on the ef-
fects of quetiapine on hallucinations and delusions us-
ing the PPRS in an uncontrolled, open-label study. The 
study induded 35 patients with advanced PO and men-
W disorders, including hallucinations, delusions, con-
fusion, and agitation. (No further breakdown of the 
demographic characteristics was provided in the arti-
cle .) The mean age of the study group was 68.4 years, 
the mean duration of PO was 11 .7 years, and the mean 
quetiapine dose was 185 mg/d (range, 100-400 
mg/d) over 12 months. The mean H&Y and UPORS-
Motor scores during on/off periods (with/without 
symptoms) were 2.9/3.6 and 35.2/ 50.8 , respectively. 
Improvements in PPRS scores, hallucinations, and de -
lusions were reported after 12 months (all, P < 0.001 ); 
no substantial worsening of UPORS-Motor scores oc-
curred (P value not reported). 
In a 24-week, single-center, uncontrolled, open-label 
study, Juncos et al40 examined 29 patients wi PO ana 
psychosis (including stable dementia an depresslo~ 
who did not wish to undergo the exten~v laboratory 
testing and monitoring needed with c1oza~ne\w who 
did not benefit from previous atypical antipsychotic 
treatment. The reasons for those treatment failures are 
presented in Table IV. Patients may have had >1 rea-
son for treatment failure. The investigators did not 
describe how many patients may have had multiple 
failures or why the number of patients with treatment 
failures was greater than the number of patients they 
studied; 86.2% (25/ 29) of the patients completed this 
24·week study. The mean quetiapine dose was 62.5 
mg/d (range, 12.5-400 mg/d) . The primary outcome 
was the change in BPRS score after 24 weeks of treat-
ment. Secondary outcomes induded NPI- Total, NPI-
2, and CGI. Improvements in the BPRS and CGI 
scores were significant (P - 0.003 and P - 0.039, re-
spectively), but the effects on the NPI- Total score did 
not reach statistical significance. It is unclear why a 
significant treatment difference in NPI-Total score was 
not found. However, the improvement in NPI- 2 score 
was statistically significant (P - 0.027). Significant im-
provement in CGI-SI score was reported in 51.7% 
(15/ 29) of patients, no substantial change was noted 
in 13.8% (4/ 29), and worsening was noted in 34.5% 
(10/ 29). The most common adverse effects reported 
were dizzine~ (13.8%; 4/ 29) and postural hypotension 
(6.9%; 2/ 29). Other adverse effects were characterized 
as mildl o mOderate and unrelated to treatment. The 
mean MMSE score was 21.2; no significant difference 
in MMSE score was found between the baseline and 
week-24 assessments. 
n 2005, Ondo et al41 conducted an RCT in 31 pa-
tients with PO and hallucinations (21 received quetia-
mne and 10 received placebo); 83.9% (26/31) of the 
patients completed the study. Treatment was discontin-
ued for 19.0% (4/ 21 ) of patients in the quetiapine 
group (2 for unrelated serious illness and 2 for lack of 
effect/poor compliance). Treatment was also discon-
tinued for 20.0% (2/ 10) of patients in the placebo 
group (for unrelated serious illness) . The investigators 
stated that the dropouts were not induded in the sta-
tistical analysis. The primary outcomes were the BPO-
HQ and the UPORS. The mean quetiapine doses were 
Table IV. Previous treatment failures for patients enrolled in the study by Juncos et al (N = 29).40 
Drug 
Clozapine 
O lanzapine 
Risperidone 
NA = not applicable. 
No. of Patients Who 
Experienced Treatment Failure$ 
17 
14 
9 
'Patients may have experienced treatment failure for> 1 reason . 
• 
Reason for Treatment Fai lure 
Unwilling to Undergo Lack of 
Testing and Monitoring Effectiveness 
2 13 
NA 12 
NA 3 
Intolerance 
15 
26 
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s200 mg/d over 3 months. No significant difference worsening of symptoms based on the UPDRS-Motor 
was found between the groups based on the BPDHQ. scores (from 40.4 to 45.7; P - NS), whereas those 
Lack of change in the BPRS score (the secondary out- without dementia did not experience any worsening of 
come) affirmed the lack of treatment difference in this motor function (from 35.7 to 35.0; P value not 
study. The lack of treatment response could be ex- reported). 
plained by the inclusion of patients with relatively mild Klein et al43 reported on the response to treatment 
symptoms at baseline (BPRS score was 11 compared with open-labeled quetiapine over 24 months to evalu-
with >20 in other studies).42.44-47 Furthermore, the ate the long-term effects on drug-induced psychosis. 
investigators reported a post hoc analysis of power at This appeared to be a continuation of the Prohorov 
0.22 and effect size of 0.35, which indicates that the study.42 Thirty-five patients (19 with dementia, 16 
study might have been underpowered. No substantial without) were recruited. The mean age was 76.1 years, 
differences in the changes in the UPDRS-ADL or and the mean duration ofPD was 10.3 years. Of the 35 
UPDRS-Motor scores were found between the groups patients, II (31.4%) completed the 2-year study, 7 of 
(P values not reported). This suggested that PD fea- whom had dementia. Based on CGI scores (the pri-
tures did not worsen with treatment. mary outcome measure), 25.7% (9/35) of the patients 
In 2006, Prohorov et a142 investigated in an open- reported good response to quetiapine, 5.7% (2/35) 
label study whether dementia would affect the response reported partial response, and 8.6% (3/35) stopped 
to quetiapine in patients with drug-induced psychosis taking quetiapine because of improvement (medication 
over 6 months. Thirty-five patients with PD and psy- no longet)"equired). The mean dose of quetiapine was 
chosis were included (19 with and 16 without demen- 93 mgJd. Caregivers served as the primary source of 
tia). The mean MMSE score was 16.3 in the group global impression. No psychometric testing was re-
with dementia and 26.1 in the group without demen- ported to support the changes in global impression. 
tia. The mean patient age was 75.5 years, and the mean TweJye patients (34 .3%) did not respond to quetiapine 
duration of PD was 10.3 years. Mixed hallucinations therapy and were switched to dozapine therapy; all 12 
and delusions were present in 65.7% (23/35) of the eSE}lnded to the switch (no statistics were reported). 
patients. Most (68.6%; 24/35) of the patients com- ~hree other patients (8.6%) had dozapine added to 
pleted the study; 26.3% (5/19) of the patie~ wi, their quetiapine therapy, but none of those patients 
dementia and 37.5% (6/16) of the patients without responded. Characteristics of these 3 patients were not 
dementia dropped out of the study (P NS) . asoqs included in the published article. 
for dropping out included lack of response in 22.9% Rabey et a144 conducted an RCT in 58 patients with 
(8/35) of patients and adverse effects (~mnolence or PD and psychosis, 79.3% (46/58) of whom were char-
orthostatic hypotension) in 8.6% (3/35) o(:'patients. acterized as having severe psychotic symptoms that 
Effectiveness results based on BPRS scores (the primary significantly affected their quality of life. Patients were 
outcome) and CGI scores were conflicting. Among the further subdivided into groups with and without de-
patients who completed the study, there was no signif- mentia (29 in each group). This study lasted 3 months. 
icant difference in BPRS scores between the groups (no The primary outcome was the change in BPRS and 
statistics were reported). However, results based on the CGI scores from baseline. The mean dose of quetiapine 
CGI suggested that PD patients with dementia were was 119 mg/d. After 3 months of treatment, no sub-
more likely than those without dementia to benefit stantial difference was found in BPRS scores between 
from quetiapine therapy for drug-induced psychosis the quetiapine and placebo groups or between the 
(50% vs 40%, respectively; Pvalue not reported). Que- groups with and without dementia (no statistics were 
tiapine doses ranged from 76 to 150 mg/d over 24 reported). Improvement was seen in 30.0% (9/30) of 
weeks. Doses tended to be higher in the group with the patients who receivedquetiapine and 46.4% (13/28) 
dementia (150.9 mg/d) than in the group without of those who received placebo. Although numerically 
dementia (76 .3 mg/d; P < 0.03). Titration in the de- this appears to favor placebo, no statistical anaJysis was 
mentia group took -2 weeks longer than in the group reported to assess significance. No treatment difference 
without dementia (5.5 vs 2.3 weeks, respectively), but was found based on the BPRS subitems of hallucina-
treatment duration was the same (24 weeks) for both tions and delusions or the UPDRS-Motor scores. Som-
groups. Final mean doses were 205 mgjd in the de- nolence was reported in 23.3% (7/30) of patients in 
mentia group and 258.3 mg/d in the group without the quetiapine group and 7.1% (2/28) of patients in 
dementia. Patients with dementia experienced a slight the placebo group; 6.7% (2/30) of patients in the que-
, 
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tiapine group stopped treatment because of somno-
lence. Orthostatic hypotension was reported in 3.3% 
(1/30) of patients taking quetiapine and none (0%; 
0/28) of those taking placebo. Eleven patients were 
hospitalized during this study because of urinary-tract 
infections (4 patients), syncope (2), acute psychosis (2), 
hip fracture (2), or chest pain (1) . Only urinary-tract 
infections and chest pain occurred more frequently in 
the quetiapine group than the placebo group . Statisti-
cal significance was not reported, and the investigators 
did not indicate whether these hospitalizations were 
considered to be treatment related. This study had a 
poor completion rate (55%). 
Kurian et al4S conducted a multicenter ReT in 40 
patients with PO (9 with dementia, 8 with Alzheimer's 
disease, and 23 with OLB). The investigators sought to 
determine the effectiveness of quetiapine in the treat-
ment of psychosis or agitation as measured by the 
change in BPRS score after 10 weeks of treatment. The 
mean dose was 120 mgjd (dose range not reported). 
The investigators were allowed to use up to 150 mg 
BID and were encouraged to titrate in increments of 
25 mgjd every 2 days to at least 100 mg/d. The study 
duration was 2.5 months, and the completion rate was 
75% (S5% in the quetiapine group, 65% in the placebo 
group). After 10 weeks of therapy, no significant differ-
ence in BPRS scores was found between the 2 groups. 
An S.2-point improvement was reported for the quetia-
pine group, which is consistent with the magnitude of 
effect seen in clozapine arms of other trials.22 A large 
treatment effect (6.1 points) was seen in the placebo 
group, which might account for the lack of statistical 
difference between the 2 groups. In addition, the in-
vestigators reported a lack of statistical difference in 
global ratings of change, which also supports a lack of 
treatment difference between placebo and quetiapine. 
No significant differences were found between the sub-
groups of patients with dementia, Alzheimer's disease, 
or OLB. The study sample size was small. Some pa-
tients without PO were included in the study, and data 
were not available to adjust the analysis to exclude 
these individuals. 
Comparison Studies 
Two clinical trials46,47 were head-to· head compari-
sons of clozapine and quetiapine (Table V). In 2004, 
Table V. Head-to-head studies of quetiapine versus dozapine.46,47 
Study 
Morgante 
et al, 
2004-% 
Merims 
et al 
200647 
Blind 
Rater 
blinded 
Rater 
blinded 
Cohort 
Size 
45 
27 
Completion 
BPRS-Total Rate; % 
Quetiapine, 37.1; 88.9 
clozapine, 37.4 
NA 59.2 
Mean Dose 
(Range), mg/d 
Quetiapine, 
91 (25-2001 
clozapine, 
26 (12.5-50) 
Quetiapine, ~.9; 
clozapine,13.1 
Duration, 
Months 
3 
5.5 
Primary 
Outcome 
Measures 
BPRS,CGI 
Results 
BPRS: clozapine, 
P < 0.001; quetiapine, 
P < 0.001; CG I: 
improved; clozapine, 
P < 0.001; quetiapine, 
P < 0.001 
NPI-Total, NPI hallucinations; 
CGIC clozapine, P < 0.002; 
quetiapine, P = NS; 
NPI delusions: 
clozapine, P < 0.Q15; 
quetiapine, P = NS; 
CGIC: clozapine, 
P < 0.001; quetiapine, 
P < 0.001 
BPRS = Brief Psychiatric Rating Scale (range. 0-108 if usingO-6 scale or 18-126 if using 1-7 scale;each of 18 items rated from not present to extremely severe}. 
CGI = Clinical Global Impression of Improvement (range. 0-7; 0 = not assessed, 4 = no change, 7 = very much worsened}. NA = not applicable; NPI-Total = 
Neuropsychiatric Inventory total sum of scores (range. 0-120; subscales for frequency (4·point scale; 4 = very frequent] and severity (3·point scale; 3 = severe~ 
CGIC = Oinical Global Impression of Change. 
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Morgante et al46 reported on a randomized, open-la-
bel, rater-blinded, comparison trial of quetiapine and 
dozapine, using the BPRS and CGI as the primary 
outcome measures; 45 patients were induded in this 
study, 40 of whom completed the study (completion 
rate, 88.9%). Three (13.0%) of23 patients in the do-
zapine group and 1 (4.5%) of22 patients in the quetia-
pine group did not complete the study. Reasons for 
discontinuation induded dizziness, severe hypotension, 
and oversedation in the dozapine group and confusion 
in the quetiapine group (1 patient each). The mean 
doses were 26 mg/ d for dozapine and 91 mg/ d for 
quetiapine. Improvement based on CGI-SI scores 
compared with baseline were reported for both groups 
after 3 months of treatment (both, P < 0.001 ). Indi-
vidual changes in BPRS scores were significant for each 
treatment group: dozapine changed from 15.5 at base -
line to 8.4 at end point (P< 0.001 ); quetiapine changed 
from 16.4 at baseline to 8.4 at end point (P< 0.001 ). 
However, Morgante et al46 reported "no statistical dif-
ference" in BPRS scores between the dozapine and 
quetiapine groups (Pvalue not reported). 
In 2006, Merims et al47 conducted a randomized, 
rater-blinded, comparative trial using the Clinical 
GlobaJ Impression of Change (CGIC), hallucination 
frequency and severity, and delusion frequency and se-
verity as outcome measures. The mean c10zapine dose 
was 13 mg/d, and the mean quetiapin ose was 90 
mg/d. The study lasted 5.5 months, and the ompl~ 
tion rate was poor (59%). Reasons for withdraw3.1 in the 
quetiapine group were lack of efficacy (4 patients) and 
sleepiness (2); reasons for withdrawal in the d ozapine 
group were decreased leukocytes (3) and difficulty 
keeping up with the weekly blood counts (1). At the 
end of the study period, improvement in CGIC scores 
over baseline were reported for both dozapine and 
quetiapine (both , P < 0.001), but no significant differ-
ence was found between the dozapine and quetiapine 
groups (no data were reported). A greater reduction in 
hallucination frequency over baseline was found with 
dozapine (P < 0.01 ) than with quetiapine (PvaJue not 
reported). After 5 months, improvement in delusions 
over baseline was reported for c10zapine (P < 0.015) 
but not for quetiapine (Pvalue not reported). Neither 
medication improved the severity of haJlucinations or 
delusions. 
Noncomparative Trial of Clozapine and 
Quetiapine Interventions 
Goetz et aJ48 described the effects of antipsychotic 
intervention on hallucination and psychosis in patients 
with PO over the long term (12 months). Two groups 
were compared: one with pharmacologic intervention 
(31 patients) and one without pharmacologic interven-
tion (33 patients). Both groups were further classified 
based on reductions in PO-related medications: those 
receiving antipsychotic medications (12 patients), those 
receiving antipsychotic medications and reductions in 
PO-related medications (19 patients), those receiving 
no antipsychotic treatment but reductions in PO-relat-
ed medications (13 patients), and those receiving non-
pharmacologic interventions only (eg, education, coun-
seling, keeping lights on at night, sleep hygiene 
recommendations) (20 patients). Clozapine therapy 
was started in 8 patients, and quetiapine therapy was 
started in 23 patients. Three patients in the quetiapine 
group had transient switches to aripiprazole but were 
restarted on quetiapine due to sedation from aripipra-
zole . The mean doses were 39 mgjd for d ozapine and 
46.7 mgjd for quetiapine. The primary end point was 
the time from the first thought disorder item on the 
UPO for.JlaJ lucinations to increase from 2 to >2. 
ore than half of the patients (59.4%; 38/64) experi-
encea the end point. The mean follow-up was 31 
months (range, 2- 110 months). Worsening ofhalluci-
ations was experienced by fewer of the patients who 
received antipsychotic medications (25 .8%; 8/31) than 
by those who did not receive antipsychotic medications 
(90.9%; 30/33). The investigators calculated a hazard 
ratio (HR) to assess the potentiaJ reduction in progres-
sion with treatment (HR - 0.156; 95% CI, 0.067-
0.363; P < 0.001 ). The investigators aJso reported a 
longer time to worsening of haJlucinations with anti-
psychotic medication use (39 vs 12 months) in those 
without antipsychotic treatment (Pvalue not reported). 
Only the group with reduction in PO-related medica-
tions experienced worsening of motor function over 
baseline, as measured on the UPORS-Motor subscale 
(P- 0.031 ). No significant changes in UPORS-Motor 
scores were noted in the antipsychotic medication 
group. 
DISCUSSION 
Study Oesigns 
Since guidelines were published in 2006, numerous 
case reports, case series, retrospective, and prospective 
observationaJ studies have been published. However, 
only 3 RCTs have appeared in the literature.4 I ,44,4S 
Two of the RCTs were conducted in patients with PO 
and dementia or OLB.44,4S Neither of those studies 
reported a difference in BPRS scores between the 
groups, but improvement based on CGI scores was 
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reported in both studies. The most common reasons 
for not completing the study conducted by Rabey et 
aJ44 included lack of response and adverse effects . How-
ever, the differences between the groups were not sta-
tistically significant. A plausible reason for the lack of 
treatment difference was the milder symptoms seen at 
baseline. 
In the study by Kurian et aJ,4S dropouts were re-
ported more frequently in the placebo group (35%) 
than in the quetiapine group (15%). The overaJl high 
dropout rate and high placebo response could have 
diluted the power of the study. Interestingly, the mag-
nitude of change in the BPRS was 8.2 points, which 
was not statistically different from that of the PSY-
CWPS (Psychosis and Clozapine in Parkinson's Dis-
ease) study.22 The third RCT, by Ondo et al,·1l had a 
strong study design but reported a lack of treatment 
difference. The milder baseline EPRS scores may ex-
plain this finding. Additional studies in larger cohorts 
are needed. 
Clozapine Studies 
The study by Gomide et aJ38 provided information 
about a Brazilian cohort. This may not be generalizable 
to other populations. The lack of standardized out-
comes and the descriptive nature of the study make--i 
difficult to draw conclusions regarding the effectiveness 
of clozapine. Pollak et aJ36 added more long-tenn per-
spective on the use of clozapine. The high relapse rate 
in those who discontinued treatment suggests thab psy-
chotic symptoms may need to be treated over longer 
periods. This needs to be confirmed in futur studies. 
The study by Fernandez et aJ37 described 5-year out-
comes and suggested that -33% of patients with PD 
and psychosis would be admitted to a nursing home 
and 44% would die over those 5 years. 
This brings up the important question of outcomes. 
To date, neuropsychiatric scales such as the EPRS serve 
as the main treatment outcome. This therapeutic goal 
is largely symptomatic . Studies should be undertaken 
to explore outcomes such as caregiver stress, function, 
and quality of life. 
Quetiapine Studies 
Seven studies were examined.39-4S Four studies39-41,44 
specifically addressed quetiapine use in PO psychosis, 
and 3 studies42,43,45 examined potential differences in 
response between PD patients with and without de-
mentia. Two studies39,4o reported a favorable benefit 
and 2 studies41 ,44 did not. Juncos et al40 and Mancini 
et al extended the current data to suggest that quetiap-
12 
ine could be beneficial and well tolerated over the long 
term. However, it should be kept in mind that neither 
study was controlled . Results of the Juncos study sup-
ported the role of quetiapine in patients in whom previ-
ous treatment with other antipsychotics (eg, dozapine, 
olanzapine, risperidone) failed. Given the recommen-
dations in the AAN guideline to use clozapine or que-
tiapine but not olanzapine, this appeared to suggest 
that quetiapine would be a reasonable alternative for 
those patients and others who did not benefit from 
treatment or do not wish to undergo the extensive test-
ing and monitoring needed with clozapine. Results of 
the study by Mancini et aJ supported a long-term role 
for quetiapine without motor worsening in patients 
with PO and psychosis. 
The RCT conducted by Rabey et al44 reported a lack 
of effectiveness with quetiapine. Possible explanations 
include the loss of power from dropouts and the high 
prevalence 06 dementia. The effects of dementia on 
drug effectiveness are not dear (discussed later) . Ondo 
et al41 also failed to find effectiveness of quetiapine in 
their Rg . H'owever, the EPRS scores at baseline in 
that study suggested milder symptoms initially. 
£rohorov et aJ42 were the first group to compare PD 
patien ~with and without dementia and the effects of 
ilementia on treatment response in psychosis. Results 
o£their 6-month study were conflicting. No substantial 
difference in BPRS scores was found; however, based 
on CGI scores, improvement was reported more fre-
quently in patients with dementia than in those without 
dementia. Unfortunately, no statistical anaJysis was 
conducted on CGI scores; therefore, the significance of 
this difference is unknown. 
Klein et al43 extended the data from the Prohorov 
study'2 to 24 months. No significant difference was 
seen in patients with dementia, and those without de-
mentia improved. Again, no statisticaJ analysis was 
reported . 
Finally, Kurian et al45 investigated a mixed cohort of 
patients with DLE, PO with dementia, and Alzheimer's 
disease with parkinsonian features. Over 2.5 months, 
no significant differences were observed in this cohort. 
Although the overall completion rate was poor, patients 
in the quetiapine group were more likely than those in 
the placebo group to complete the study (85% vs 65%, 
respectively). It is likely that the poor completion rate 
diluted the study's statistical power. Currently, it is un-
dear whether patients with dementia respond differ-
ently from those without dementia. Further research is 
needed to investigate this issue. A study design barrier 
may explain the high dropout rate in this population 
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with advanced disease. 
Comparative Trials 
Two comparative trials4(i,47 were reviewed. Both 
studies confirmed that clozapine and quetiapine were 
not significantly different in terms of effectiveness 
when used to manage hallucinations and psychosis in 
patients with PD. Differences in tolerability were less 
clear given the small sample sizes. Both studies were 
limited by their open-label design and lack of a placebo 
group. However, given the acceptance of clozapine as 
"probably effective, .. 2o it is reasonable to conduct fu-
ture studies using clozapine as the active comparator 
instead of a placebo. 
Other Atypical Antipsychotics 
Although studies of aripiprazole, olanzapine, risperi-
done, and ziprasidone have been published, all were 
small case series. Miyasaki et al20 concluded that olan-
zapine should always be avoided in patients with PD. 
Since publication of the 2006 AAN guideline, few data 
have been published to suggest any changes in practice. 
Nevertheless, the recent literature adds to the under-
standing of the advantages and disadvantages of using 
clozapine or quetiapine. Fernandez et aJ37 appeared to 
be the first group to report on clinical outcomes of 
5-year mortality with c10zapine in PO psychosi . 
CONClUSIONS 
Published data regarding the trea~n of psychosis 
and hallucinosis in patients with PO are- scant ap d lim-
ited by the study designs. Based on the few trialS that 
have been published, both clozapine and quetiapine are 
reasonable pharmacotherapeutic options for moderate 
to severe psychosis in patients with PD. There is not 
enough evidence for or against other atypical antipsy-
chotics to draw any conclusions regarding their use in 
these patients. Currently, it is unclear whether patients 
with PO and dementia respond differently to quetiap-
ine therapy than patients without dementia . Future re-
search should continue to explore the presentation of 
psychosis in patients with PO and their treatment re-
sponse patterns. 
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